Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

A Colorimetric ELISA Enabling Quantification of APP Δ C31 in Cell Lysates and Cerebrospinal Fluid

John Zielinski1,Karen Poksay2, Varghese John2 and Michael Mullenix1
1Enzo Life Sciences,Inc., Farmingdale, NY 11735, USA
2The Buck Institute for Research on Aging, Novato, CA 94945, USA

Featured Product: APP ΔC31 ELISA kit

> Download the complete application note


The amyloid precursor protein (APP) undergoes a variety of modifications through enzymatic cleavage leading to the formation of pro-Alzheimer’s disease (AD) and anti-AD biologically active peptides. One such cleavage product, APP δC31 results from the caspase cleavage of the full length APP protein (APP695) at amino acid Asp664 as well as the concomitant formation of the 31 amino acid C-terminal peptide (C31). The APP δC31 truncated protein has been shown to accumulate in brain tissue of AD patients as well as in brain tissue from AD model mice and is suggested to play a role in the etiology of the disease. To enable the quantitative measurement of APP δC31 formation in cells and tissues we have developed a colorimetric ELISA assay. The assay is highly specific to APP δC31 exhibiting no cross-reactivity to APP. The assay has a sensitivity of 1 pM with an assay range of 12 to 1500 pM. The ELISA has been validated for use in cell lysates and cerebral spinal fluid and is indicated for use in serum and plasma. The applicability of the assay to drug screening studies in cell culture was demonstrated through simvastatin induction of APP δC31 production in the presence of increasing concentrations of a pan caspase inhibitor. The amount of APP δC31 in cell lysates decreased with increased concentration of caspase inhibitor. Establishing the ability of the assay to function in a wide variety of matrices provides the opportunity to evaluate APP δC31 as a biomarker for diagnosing and monitoring Alzheimer's disease.

Read More about Neuroscience


Our bi-weekly TechNotes are an easy way for you to keep in touch with how Enzo Life Sciences is living up to our motto: Scientists Enabling Healthcare™. Each TechNote connects recently published research with one or more of the many solutions Enzo provides for scientists across the life sciences, drug development, and clinical research communities.

Neuroscience TechNotes

Neuroscience Product Range

Fueling Discovery in the Etiology, Pathology, and Treatment of Neurodegenerative Disease.

Cancer Research


Recommend this page